Compare IR & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IR | TEVA |
|---|---|---|
| Founded | 1859 | 1901 |
| Country | United States | Israel |
| Employees | N/A | 32842 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.1B | 33.5B |
| IPO Year | 2017 | N/A |
| Metric | IR | TEVA |
|---|---|---|
| Price | $83.85 | $31.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $96.00 | $38.63 |
| AVG Volume (30 Days) | 3.1M | ★ 3.9M |
| Earning Date | 04-28-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.10% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.45 | N/A |
| Revenue | ★ $2,375,400,000.00 | N/A |
| Revenue This Year | $7.10 | N/A |
| Revenue Next Year | $4.78 | $2.97 |
| P/E Ratio | $57.73 | ★ $28.19 |
| Revenue Growth | ★ 22.48 | N/A |
| 52 Week Low | $72.45 | $14.99 |
| 52 Week High | $100.96 | $37.35 |
| Indicator | IR | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 48.76 | 51.72 |
| Support Level | $75.64 | $30.70 |
| Resistance Level | $84.62 | $32.40 |
| Average True Range (ATR) | 2.76 | 0.83 |
| MACD | 0.17 | 0.04 |
| Stochastic Oscillator | 27.48 | 42.08 |
Ingersoll Rand was formed through the merger of Gardner Denver and Ingersoll Rand's industrial segment. The firm's portfolio consists of two business lines: industrial technologies and services, and precision and science technologies. Ingersoll Rand serves a variety of end markets, including industrial, medical, and energy. Its broad portfolio of products includes compression, blower and vacuum, and fluid management. Ingersoll Rand generated roughly $7.7 billion in revenue in 2025.
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.